Back to News & Events

Skincare Manufacturing Company, Biocogent, Plans $10 million Expansion in North Bellport

We have exciting news to share for one of our Cfb clients Biocogent, a research and development biotechnology company that manufactures ingredients used in topical and medical skin care products. The company has recently closed a $10 million deal with Town of Brookhaven Industrial Development Agency (IDA)  to establish a three-building campus in North Bellport and invest further in infrastructure and equipment and bring outsourced manufacturing back to Long Island, expanding from their previous 12,000 square foot facility at Stony Brook University’s Long Island High Tech Incubator.

“We are excited to have the opportunity to work with the Brookhaven IDA to enable us to expand our business operation on Long Island,” said Joseph Ceccoli, President and CEO of Biocogent. “We share a strong mutual commitment to Long Island’s continued growth as a biotechnology leader in the region.”

“High-tech, well-paying manufacturing and R&D jobs like what Biocogent will bring to the Town of Brookhaven is what will help stem the brain drain of our young people,” said Frederick C. Braun III, Chairman of the Town of Brookhaven Industrial Development Agency. “The economic future of Long Island depends on attracting and retaining companies like Biocogent.”

The expansion of Biocogent’s operation will require a $10 million capital investment and additional personnel for its Bellport location. Biocogent will retain its operations and personnel currently located at the Stony Brook Long island High Technology Incubator.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 2237
                    [post_author] => 3
                    [post_date] => 2016-06-07 15:14:28
                    [post_date_gmt] => 2016-06-07 15:14:28
                    [post_content] => Traverse Biosciences has announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors. The Research Foundation for the State of New York (RF/SUNY) also participated in the financing, as part of an exclusive license and option agreement executed last year that gave Traverse Biosciences access to the relevant intellectual property for use in animal and human health.

Traverse Biosciences, which began when CEO Joseph Scaduto was serving as a BioEntrepreneur-in-Residence for the Center for Biotechnology, is working to commercialize its proprietary library of Stony Brook University invented chemically-modified curcumins for the treatment of chronic inflammatory conditions and cancers affecting humans and animals.

Read more about Traverse and the recent financing:

 

 
                    [post_title] => Traverse Biosciences Secures $500k Seed Financing
                    [post_excerpt] => Traverse Biosciences announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors.
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => traverse-biosciences-secures-500k-seed-financing
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2016-06-07 15:14:28
                    [post_modified_gmt] => 2016-06-07 15:14:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=2237
                    [menu_order] => 177
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 3269
                    [post_author] => 3
                    [post_date] => 2019-06-10 15:25:24
                    [post_date_gmt] => 2019-06-10 15:25:24
                    [post_content] => The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program recently hosted a webinar to assist interested applicants with understanding proposal preparation, federal guidelines and resources, the funding process, and address general concerns.

The webinar presentation, recording, and transcript are now available (via web and attachments) for your reference. (Please be advised, an automated transcription service was used, and there may be grammatical errors and typos in the transcript.) We have done our best to correct as many errors as possible, but you are encouraged to reach out to us by email at sbir@od.nih.gov if anything remains unclear.
- Webinar SlidesRecording
- Transcript

HHS SBIR and STTR Omnibus grant solicitations permit researcher-initiated topics around health, medicine and life science to be submitted for funding consideration. With any specific idea, you should speak directly with a HHS SBIR/STTR program manager at least a month BEFORE the deadline to gauge their interest.

You can find the HHS SBIR/STTR Omnibus Solicitations, and all of other SBIR/STTR solicitations on the Funding page of the SBIR/STTR Website: https://sbir.nih.gov/funding.

Be sure to also check the targeted funding announcements page, https://sbir.nih.gov/funding/individual-announcements. NIH Institutes and Centers will issue targeted SBIR/STTR grant solicitations around specific, high-priority research areas.

The next submission deadline is September 5, 2019.
                    [post_title] => SBIR/STTR Omnibus Webinar Recording, Transcript, and Slides Available
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => sbirsttr-omnibus-webinar-recording-transcript-and-slides-available
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2019-06-10 15:25:24
                    [post_modified_gmt] => 2019-06-10 15:25:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3269
                    [menu_order] => 94
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 4863
                    [post_author] => 4
                    [post_date] => 2025-05-01 12:34:41
                    [post_date_gmt] => 2025-05-01 16:34:41
                    [post_content] => 

Pragma Bio, a venture highlighted at the Center for Biotechnology's 2024 Life Sciences Summit this past fall, has signed a $3.1M deal with Syntekabioto to co-develop drug candidates sourced from gut microbiota. Pragma, which mines microbiome-based therapies for cancer and autoimmune diseases, will provide the compounds and Syntekabio will handle the algorithmic optimization.

Read more about the Pragma, Syteka and their partnership here: https://www.koreabiomed.com/news/articleView.html?idxno=27024

[post_title] => Pragma Bio Inks Co-Development Deal with Syntekabio [post_excerpt] => Life Sciences Summit 2024 Venture Spotlight Company Pragma Bio signs 3.1M co-development deal. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => pragma-bio-inks-co-development-deal-with-syntekabio [to_ping] => [pinged] => [post_modified] => 2026-03-10 14:20:26 [post_modified_gmt] => 2026-03-10 18:20:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4863 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 3 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 2237 [post_author] => 3 [post_date] => 2016-06-07 15:14:28 [post_date_gmt] => 2016-06-07 15:14:28 [post_content] => Traverse Biosciences has announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors. The Research Foundation for the State of New York (RF/SUNY) also participated in the financing, as part of an exclusive license and option agreement executed last year that gave Traverse Biosciences access to the relevant intellectual property for use in animal and human health. Traverse Biosciences, which began when CEO Joseph Scaduto was serving as a BioEntrepreneur-in-Residence for the Center for Biotechnology, is working to commercialize its proprietary library of Stony Brook University invented chemically-modified curcumins for the treatment of chronic inflammatory conditions and cancers affecting humans and animals. Read more about Traverse and the recent financing:     [post_title] => Traverse Biosciences Secures $500k Seed Financing [post_excerpt] => Traverse Biosciences announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-secures-500k-seed-financing [to_ping] => [pinged] => [post_modified] => 2016-06-07 15:14:28 [post_modified_gmt] => 2016-06-07 15:14:28 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2237 [menu_order] => 177 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 282 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Traverse Biosciences Secures $500k Seed Financing

More Information

SBIR/STTR Omnibus Webinar Recording, Transcript, and Slides Available

More Information

Pragma Bio Inks Co-Development Deal with Syntekabio

More Information